Each year, a staggering 13 million adults across the country grapple with the weight of major depression. Among those seeking care, nearly 40% find no respite or full recovery through conventional antidepressant medications.
For those battling the relentless darkness of depression, Ketamine— initially used as an anesthesia medicine in the 1960s, represents a powerful tool in the fight against Major Depressive Disorder and Treatment Resistant Depression (TRD).
Spravato®, approved by the. FDA in 2019 for use in conjunction with an oral antidepressant offers new hope for individuals with Major Depressive Disorder that is treatment-resistant or includes suicidal thoughts. More easily deliverable than IV Ketamine, Spravato® is an intranasal spray that harnesses the power of Esketamine, a potent ketamine derivative. As provided in a comfortable, supervised, and supportive in-office setting Spravato® offers rapid relief from depression symptoms while allowing the oral antidepressant medication to take effect.
Refer a patient, friend, or make the decision for yourself to feel better. Contact us today to set up an initial free consultation with an Intake Coordinator.
Duluth
St. Cloud